Last updated: September 24, 2026
Capromab pendetide, marketed as ProstaScint, is a discontinued or commercially inactive prostate-cancer imaging biologic rather than a growth-market therapeutic. Its financial trajectory followed a short commercial window: initial adoption as an immunoscintigraphy product, limited expansion because of diagnostic performance and workflow constraints, then displacement by PSMA-targeted PET agents. Current revenue, market share, and generic-entry exposure are effectively zero in the United States because the product is no longer a meaningful commercial competitor.
Capromab Pendetide Market Dynamics and Financial Trajectory
What is capromab pendetide and how was it used?
Capromab pendetide is a murine monoclonal antibody fragment directed against prostate-specific membrane antigen, or PSMA. It is labeled with indium-111 and administered intravenously for planar or SPECT imaging.
The product was marketed as ProstaScint. The FDA approved it in 1996 as an adjunct to conventional diagnostic evaluation in:
- Newly diagnosed, biopsy-confirmed prostate cancer patients at high risk for pelvic lymph-node metastases.
- Patients with suspected recurrence based on elevated prostate-specific antigen, or PSA.
Capromab pendetide was an imaging agent, not a prostate-cancer treatment. Its clinical and commercial value depended on its ability to identify prostate-cancer deposits before surgery or during recurrence evaluation.
The product’s original PSMA rationale was commercially attractive, but the antibody recognized an intracellular or non-optimally accessible epitope in many tumor settings. That limited sensitivity and reduced its ability to compete with later PSMA PET radiopharmaceuticals.
When did ProstaScint lose commercial relevance?
ProstaScint lost relevance in stages rather than through a single regulatory event.
| Period |
Market development |
Commercial effect |
| 1996-early 2000s |
FDA approval and introduction of ProstaScint |
Created a niche market for prostate-cancer staging and recurrence imaging |
| Mid-2000s |
Adoption remained concentrated in specialized centers |
Limited scale and modest repeat utilization |
| 2010s |
Greater use of multiparametric MRI, improved conventional imaging, and newer molecular imaging approaches |
Reduced demand for antibody-based SPECT imaging |
| 2020-2023 |
FDA approvals of PSMA PET agents, including gallium-68 PSMA-11 and fluorine-18 agents |
Accelerated replacement of ProstaScint |
| Current period |
No meaningful U.S. commercial presence |
Revenue and launch risk are negligible |
The key market failure was technological. ProstaScint used a relatively slow antibody-based platform and an indium-111 SPECT workflow. Modern PSMA PET products offer higher-resolution imaging, faster clinical decision-making, and broader utility for staging and biochemical recurrence.
The FDA approved gallium-68 gozetotide, also known as Ga-68 PSMA-11, in 2020 and 2021 for PSMA PET imaging in prostate cancer. The agency later approved piflufolastat F-18 and flotufolastat F-18. These products target the same broad biological signal but use PET rather than antibody-based SPECT imaging (U.S. Food and Drug Administration [FDA], 2020, 2021, 2023).
What was the financial trajectory of capromab pendetide?
Public financial disclosure does not provide a reliable, current product-level revenue series for ProstaScint. Historical filings from Cytogen reported corporate product revenue and development expenses, but ProstaScint was not consistently disclosed as a standalone revenue line in a way that supports a precise longitudinal estimate.
The economic trajectory can be characterized as follows:
- Initial commercial monetization after FDA approval.
- Gradual stabilization as a niche imaging product.
- Limited expansion because of reimbursement, imaging-center requirements, and clinical-performance constraints.
- Structural decline as PSMA PET replaced antibody-based SPECT.
- Commercial inactivity after the product ceased to be a relevant U.S. imaging option.
Capromab pendetide had a different financial profile from a therapeutic biologic. It was administered episodically, did not generate chronic prescription refills, and required nuclear-medicine infrastructure. Revenue therefore depended on procedure volume, imaging-center access, reimbursement, and physician confidence in the scan rather than on a recurring drug-treatment population.
Historical financial characteristics
| Financial factor |
Effect on ProstaScint |
| Treatment duration |
One-time or episodic imaging use, limiting recurring revenue |
| Manufacturing |
Required a radiolabeled antibody product with specialized handling |
| Distribution |
Dependent on nuclear-medicine and radiopharmacy logistics |
| Reimbursement |
Dependent on imaging coverage and clinical acceptance |
| Clinical adoption |
Constrained by sensitivity, specificity, and interpretation complexity |
| Competitive pressure |
Increased sharply as PSMA PET became available |
| Current revenue |
No material current U.S. revenue is publicly evident |
The product’s commercial ceiling was lower than that of a therapeutic oncology biologic because the addressable market was limited to selected diagnostic situations. The product also competed with non-drug imaging modalities, including CT, MRI, bone scanning, and later PET.
Which companies commercialized or challenged capromab pendetide?
Cytogen was the company most closely associated with ProstaScint’s development and commercialization. The product was part of Cytogen’s oncology-focused portfolio and corporate strategy before the company’s assets and operations were affected by later corporate transactions.
The competitive landscape changed from antibody imaging to PSMA-targeted PET. Relevant modern competitors include:
| Product |
Active imaging agent |
Company or commercial sponsor |
Imaging platform |
| ProstaScint |
Indium-111 capromab pendetide |
Cytogen historically |
SPECT |
| Illuccix |
Gallium-68 gozetotide, also Ga-68 PSMA-11 |
Telix |
PET |
| Locametz |
Gallium-68 gozetotide kit |
Novartis |
PET |
| Pylarify |
Piflufolastat F-18 |
Lantheus |
PET |
| Posluma |
Flotufolastat F-18 |
Blue Earth Diagnostics, part of Bracco |
PET |
These products did not need to prove only that they could detect prostate cancer. They competed on resolution, speed, lesion localization, clinical guidelines, reimbursement, radiopharmacy availability, and integration into treatment planning.
How strong was the capromab pendetide patent estate?
The patent estate no longer provides a meaningful commercial barrier. Capromab pendetide was approved in the 1990s, so any original composition, antibody, formulation, or use patents would generally have reached the end of their ordinary U.S. patent terms by the present period, subject to individual patent histories and patent-term adjustments.
The product also lacks the characteristics that make patent layering especially valuable in current oncology markets:
- It does not have a new long-lived formulation franchise.
- It does not have a commercially important delivery device.
- It does not have a durable manufacturing barrier that prevents replacement by PET agents.
- It does not have a current high-value method-of-use market.
- It is not a biosimilar reference product with an active biologic market.
No active U.S. exclusivity position appears to support a current commercial relaunch. The principal barrier is not patent enforcement. It is the absence of a competitive clinical and reimbursement proposition.
What is the FDA and Orange Book status of capromab pendetide?
ProstaScint was FDA approved as a diagnostic radiopharmaceutical. Its regulatory status should be distinguished from that of a currently marketed therapeutic biologic.
The FDA product record and historical labeling establish the original approval and indication. Current commercial status is inactive or discontinued in the U.S. market. The product is not a current growth opportunity based on FDA exclusivity, and it is not a standard Orange Book franchise comparable to a marketed small-molecule medicine with active listed patents.
Orange Book analysis is also less central because capromab pendetide is a radiolabeled biologic imaging product rather than a conventional oral or injectable therapeutic. Any current investment thesis would depend on regulatory reactivation, manufacturing reinstatement, clinical redevelopment, and a new market position, not on residual Orange Book exclusivity.
What generic entry risks exist for capromab pendetide?
Traditional generic-entry risk is low because the product itself is no longer a material commercial market. The more important risk is substitution by clinically superior imaging products.
| Risk category |
Current assessment |
| Paragraph IV challenge |
Low practical significance because there is no material active commercial franchise |
| Biosimilar competition |
Not a meaningful current issue |
| Authorized generic risk |
Not commercially relevant |
| Therapeutic substitution |
Not applicable because the product is diagnostic |
| Technology substitution |
Very high; PSMA PET has displaced antibody SPECT |
| Reimbursement erosion |
High during the product’s mature phase |
| Manufacturing interruption |
High because specialized radiolabeling and distribution were required |
If a company attempted to relaunch capromab pendetide, it would face a more serious threat from competing imaging technology than from a conventional generic applicant.
What manufacturing and intellectual-property barriers affected the product?
Capromab pendetide required production of a monoclonal antibody, quality control of the antibody conjugate, radiolabeling with indium-111, and distribution through nuclear-medicine channels. These requirements created operational friction:
- Short radiopharmaceutical logistics windows.
- Specialized manufacturing and release testing.
- Dependence on qualified nuclear pharmacies and imaging centers.
- Greater handling complexity than conventional injectable drugs.
- Limited scalability outside established radiopharmaceutical networks.
These barriers protected the product operationally during its commercial period but did not create a durable moat. Once PET-based PSMA agents became available, the same infrastructure burden became a disadvantage.
What licensing or settlement agreements affected capromab pendetide?
No current licensing or patent-settlement arrangement appears to be a material driver of capromab pendetide’s market position. The product’s decline was primarily caused by clinical and technological displacement, not by a public generic settlement that delayed or accelerated market entry.
The economically relevant rights issue is historical ownership and commercialization responsibility. Current value would require confirmation of antibody rights, manufacturing know-how, regulatory records, trademarks, and any surviving territorial rights. Those rights, standing alone, would not restore commercial value without new clinical evidence and a modern imaging strategy.
How does capromab pendetide compare with current PSMA PET products?
| Attribute |
Capromab pendetide |
Current PSMA PET agents |
| Target concept |
PSMA-directed antibody |
PSMA-directed small-molecule ligands |
| Radionuclide |
Indium-111 |
Gallium-68 or fluorine-18 |
| Imaging |
SPECT or planar imaging |
PET |
| Speed |
Slower antibody biodistribution and imaging workflow |
Faster imaging workflow |
| Resolution |
Lower than modern PET |
Higher |
| Clinical role |
Historical staging and recurrence adjunct |
Staging, biochemical recurrence, and treatment selection |
| Market position |
Commercially inactive |
Active and expanding |
| Revenue outlook |
Negligible |
Supported by oncology imaging growth |
The comparison explains the financial outcome. Capromab pendetide had biological validation around PSMA but used a delivery and imaging platform that became obsolete relative to PET.
What is the investment outlook for capromab pendetide?
The base-case outlook is no material standalone revenue. A relaunch would require:
- Reestablished manufacturing capacity.
- A current FDA regulatory strategy.
- New comparative clinical trials against PSMA PET.
- Evidence of a patient population not adequately served by PET.
- Reimbursement support.
- A differentiated use in settings such as resource-limited imaging markets.
That burden is substantial. The product’s historical approval does not eliminate the need to demonstrate contemporary clinical value. A new owner would also compete against established PSMA PET suppliers with stronger commercial infrastructure and more current clinical evidence.
Key Takeaways
- Capromab pendetide was a first-generation PSMA-directed imaging biologic marketed as ProstaScint.
- FDA approval occurred in 1996 for selected prostate-cancer staging and recurrence evaluations.
- Its commercial model was episodic diagnostic imaging, not recurring therapeutic treatment.
- Public filings do not support a reliable current product-level revenue estimate.
- The product lost commercial relevance because PSMA PET agents provided better imaging performance and workflow.
- Current generic, biosimilar, and Paragraph IV risks are low in practical terms.
- The main commercial threat was technological substitution, not patent expiry alone.
- No meaningful current U.S. revenue or active exclusivity franchise is evident.
- A relaunch would require major regulatory, manufacturing, clinical, and reimbursement investment.
FAQs
Is capromab pendetide still available in the United States?
Capromab pendetide is not a meaningful current U.S. commercial product. ProstaScint has been displaced by newer PSMA PET radiopharmaceuticals.
Was capromab pendetide a treatment for prostate cancer?
No. It was a diagnostic imaging agent used to support staging and recurrence evaluation.
Did capromab pendetide generate blockbuster revenue?
No public evidence supports blockbuster-scale revenue. Its market was constrained by episodic use, specialized imaging infrastructure, reimbursement limitations, and competing diagnostic technologies.
Is capromab pendetide a biosimilar opportunity?
No. It is not a current reference biologic with an active therapeutic biosimilar market. Any redevelopment would be a diagnostic radiopharmaceutical project rather than a conventional biosimilar launch.
Why did PSMA PET replace ProstaScint?
PSMA PET products generally provide higher-resolution imaging, improved lesion localization, faster workflows, and broader clinical utility than indium-111 antibody-based SPECT imaging.
References
-
Cytogen Corporation. (2008). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (1996). ProstaScint (capromab pendetide) prescribing information. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2020). FDA approves first PSMA-targeted PET imaging drug for men with prostate cancer. https://www.fda.gov
-
U.S. Food and Drug Administration. (2021). FDA approves Pylarify for prostate cancer imaging. https://www.fda.gov
-
U.S. Food and Drug Administration. (2023). FDA approves Posluma for prostate cancer imaging. https://www.fda.gov
-
National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Prostate cancer. NCCN.
